NSAID RCT for Prevention of Altitude Sickness
Anahtar kelimeler
Öz
Tarih
Son Doğrulandı: | 04/30/2012 |
İlk Gönderilen: | 04/12/2012 |
Tahmini Kayıt Gönderildi: | 05/22/2012 |
İlk Gönderilen: | 05/24/2012 |
Son Güncelleme Gönderildi: | 05/22/2012 |
Son Güncelleme Gönderildi: | 05/24/2012 |
Fiili Çalışma Başlangıç Tarihi: | 06/30/2012 |
Tahmini Birincil Tamamlanma Tarihi: | 09/30/2012 |
Tahmini Çalışma Tamamlanma Tarihi: | 09/30/2012 |
Durum veya hastalık
Müdahale / tedavi
Drug: Ibuprofen 600mg orally three times daily
Evre
Kol Grupları
Kol | Müdahale / tedavi |
---|---|
Experimental: Ibuprofen Ibuprofen 600mg taken three times daily for four days. | |
Placebo Comparator: placebo Avicel placebo capsules three times daily for four days |
Uygunluk kriterleri
Çalışmaya Uygun Yaşlar | 18 Years İçin 18 Years |
Çalışmaya Uygun Cinsiyetler | All |
Sağlıklı Gönüllüleri Kabul Ediyor | Evet |
Kriterler | INCLUSION CRITERIA: Active duty military Current in their medical screening EXCLUSION CRITERIA: Upper respiratory tract infection or influenza Have had a reaction to Ibuprofen, aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs). Stayed the night at an altitude of greater than 6,700 feet within the last 7 days Headache at baseline Have altitude sickness or more than one mild symptom of any severity on the Lake Louise Questionnaire including headache, poor appetite, nausea, vomiting, fatigue, weakness, dizziness, and/or poor sleep (insomnia) Low blood oxygen or low oxygen saturation (<90%) Pregnant or cannot exclude the possibility of being pregnant, or have missed menses by over 7 days. Have taken any of the following in 48 hours preceding enrollment: acetazolamide/Diamox, steroids (dexamethasone/Decadron, prednisone), theophylline, or diuretics such as Lasix Have taken any of the following within 12 hours preceding enrollment: Ibuprofen/Motrin, Naprosyn/Naproxen/Aleve, aspirin, or Acetaminophen/Tylenol. Have taken any other medication that may be known to have potential for drug-drug interactions with ibuprofen, including (but not limited to): ACE-inhibitor antihypertiensives, thiazide diuretics, furosemide, lithium, methotrexate, and H-2 Agonists. Have any medical conditions which may make participation hazardous (*by self-report which can be clarified before enrollment with the study physicians as necessary), including: - Heart disease - Congestive heart failure, heart attack in the last month or severe coronary artery disease, or significant heart valve problems or other congenital problems. - Lung disease - Restrictive lung disease, chronic obstructive pulmonary disease (COPD), severe obstructive sleep apnea, or pulmonary hypertension of any cause. - Neurological disorders - Hydrocephalus, history of brain tumor, history of severe brain trauma or coma, pseudotumor cerebri, or severe uncontrolled headaches/migraine disorder (as diagnosed by a doctor). - Gastrointestinal - Known stomach ulcer or history of gastrointestinal bleeding. - Blood disorders - Anemia, leukemia, or other coagulopathies of any kind. - Kidney disease - Kidney failure or other known kidney disease. General - The Principal Investigator and co-investigator reserve the right to exclude a potential participant with conditions that in their judgment are not listed above, but which would reasonably represent concern for the participant's health and welfare, including (but not limited to) conditions that may directly antagonize mechanisms of acclimatization to altitude, organ failure, metastatic/malignant neoplasm, space-occupying brain lesions or diagnoses typically known to raise intracranial pressure, and disorders that are likely to antagonize adequate respiration, blood oxygenation, and/or circulation. |
Sonuç
Birincil Sonuç Ölçütleri
1. Change in the incidence of AMS as measured on the Lake Louise AMS Questionnaire across the study. [Twice daily]
İkincil Sonuç Ölçütleri
1. 1. Change in High Altitude Headache measured by the Visual Analog Scale (VAS) across the study. [Twice daily]
2. 2. Change in cognitive performance as measured by King-Devick across the study. [Twice daily]
3. 3. Change in the presence of anxiety and somatic symptoms using the BSI-12 screening tool across the study [Twice daily]
4. 4. Change in the oxygen concentration using Pulse Oximetry across the study. [Twice daily]
5. 5. Change in hydration status as measured by urine specific gravity across the study. [Twice daily]
6. 6. Change in HAH incidence and severity as measured on the Lake Louise AMS Questionnaire across the study. [Twice daily]
7. 7. Change in cognitive performance as measured by the Quickstick across the study [Twice daily]
8. 8. Change in the presence of anxiety and somatic symptoms using the GAD-2 screening tool across the study [Twice daily]
9. 9. Incidence of severe AMS as measured by a score of 6 or greater on the Lake Louise AMS Questionnaire. [Twice Daily]